Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Mar;35(3):261–264. doi: 10.1111/j.1365-2125.1993.tb05693.x

Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.

P Sheldon 1, P Pell 1
PMCID: PMC1381572  PMID: 8097101

Abstract

1. Mice, whose drinking water contained sulphasalazine, sulphapyridine or 5-amino-salicylic acid, received an antigenic challenge by cholera toxin administered either orally or systemically. 2. Sulphasalazine treated mice made less specific antibody of IgA class provided the antigen also was administered orally (P = 0.009 for days 7-28). When the antigen was administered systemically, there was a vigorous anti-cholera toxin antibody response of IgG class, and a lesser IgM but only a weak IgA response. The effect of sulphasalazine in this case was confined to the IgG response, which was significantly suppressed on day 28 (P = 0.008). 3. Sulphapyridine and 5-amino salicylic acid had no significant effect on the anti-cholera toxin (CT) responses of all three classes. 4. It therefore appears that in this model, only sulphasalazine is capable of influencing the humoral immune system, the antibody class affected depending on the route of entry of antigen. This may have implications for conditions such as rheumatoid arthritis and chronic inflammatory bowel disease, for which sulphasalazine has been found useful.

Full text

PDF
261

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali A. T., Basran G. S., Morley J. Mode of action of sulphasalazine: an alternative view. Lancet. 1982 Feb 27;1(8270):506–507. doi: 10.1016/s0140-6736(82)91474-x. [DOI] [PubMed] [Google Scholar]
  2. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  3. Comer S. S., Jasin H. E. In vitro immunomodulatory effects of sulfasalazine and its metabolites. J Rheumatol. 1988 Apr;15(4):580–586. [PubMed] [Google Scholar]
  4. Dyckner T., Wester P. O. Effect of magnesium on blood pressure. Br Med J (Clin Res Ed) 1983 Jun 11;286(6381):1847–1849. doi: 10.1136/bmj.286.6381.1847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Enders G. A., Delius M., Ballhaus S., Brendel W. Role of Peyer's patch in the intestinal immune response to cholera toxin in enterically immunized rats. Infect Immun. 1987 Sep;55(9):1997–1999. doi: 10.1128/iai.55.9.1997-1999.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Farr M., Tunn E., Crockson A. P., Bacon P. A. The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine. Clin Rheumatol. 1984 Dec;3(4):473–481. doi: 10.1007/BF02031270. [DOI] [PubMed] [Google Scholar]
  7. Fujiwara M., Mitsui K., Ishida J., Yamamoto I. The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells. Immunopharmacology. 1990 Jan-Feb;19(1):15–21. doi: 10.1016/0162-3109(90)90022-7. [DOI] [PubMed] [Google Scholar]
  8. Jertborn M., Svennerholm A. M., Holmgren J. Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine. Int Arch Allergy Appl Immunol. 1984;75(1):38–43. doi: 10.1159/000233587. [DOI] [PubMed] [Google Scholar]
  9. Pullar T., Hunter J. A., Capell H. A. Which component of sulphasalazine is active in rheumatoid arthritis? Br Med J (Clin Res Ed) 1985 May 25;290(6481):1535–1538. doi: 10.1136/bmj.290.6481.1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Shanahan F., Niederlehner A., MacDermott R. P., Stenson W. F., Kane M. G., Targan S. Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes. Immunopharmacology. 1986 Apr;11(2):111–118. doi: 10.1016/0162-3109(86)90031-7. [DOI] [PubMed] [Google Scholar]
  11. Sheldon P., Pell P., McBurney A. Effect of sulphasalazine on antibody response to oral antigen. Br J Rheumatol. 1992 Dec;31(12):819–822. doi: 10.1093/rheumatology/31.12.819. [DOI] [PubMed] [Google Scholar]
  12. Sheldon P., Webb C., Grindulis K. A. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action? Br J Rheumatol. 1988 Oct;27(5):344–349. doi: 10.1093/rheumatology/27.5.344. [DOI] [PubMed] [Google Scholar]
  13. Sircar J. C., Schwender C. F., Carethers M. E. Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170–172. doi: 10.1016/0006-2952(83)90673-1. [DOI] [PubMed] [Google Scholar]
  14. Symmons D. P., Salmon M., Farr M., Bacon P. A. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. J Rheumatol. 1988 Apr;15(4):575–579. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES